Clinical Trials

85 enrolled

Triple Negative Breast Neoplasms

NCT07320508 2026-01-21

EIC-SNACC

100 enrolled

Carcinoma, Adenoid Cystic

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

140 enrolled

Breast Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

144 enrolled

Breast Neoplasms

NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

60 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

51 enrolled

Triple Negative Breast Neoplasms

NCT03515798 2025-09-12

PELICAN

52 enrolled

Inflammatory Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

520 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT06860529 2025-06-23

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

357 enrolled

HR+/HER2- Breast Cancer

NCT01630083 2025-06-15

FAST

252 enrolled

Gastrointestinal

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

NCT06964906 2025-05-11

NeoHunter

140 enrolled

Breast Neoplasms

NCT04668365 2025-04-25

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Suspended

59 enrolled

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

NCT05024734 2025-03-11

GAIN INST

34 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT05165225 2024-11-29

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

48 enrolled

Breast Neoplasms

NCT06705127 2024-11-26

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

30 enrolled

HR-positive,HER2-negative Breast Cancer

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT06470633 2024-06-24

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

29 enrolled

Breast Neoplasms

NCT06389006 2024-05-23

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

79 enrolled

Breast Neoplasms

NCT04418154 2024-05-21

NeoTENNIS

70 enrolled

Triple Negative Breast Neoplasms

NCT06404463 2024-05-08

QUEEN-Neo

76 enrolled

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT06371807 2024-04-17

KEYPARTNER

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06227117 2024-03-19

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

120 enrolled

Breast Neoplasms

NCT06309732 2024-03-13

GAMEC-II

36 enrolled

Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT06227065 2024-01-26

POLO

28 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05978648 2023-11-30

SMA-BC-002

116 enrolled

Breast Neoplasms

NCT02287129 2023-11-28

MEMORI

75 enrolled

Gastrointestinal

Adenocarcinoma of the Esophagogastric Junction

NCT05983094 2023-08-09

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

181 enrolled

Breast Neoplasms

NCT05887726 2023-07-27

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

35 enrolled

Triple Negative Breast Neoplasms

NCT04433156 2023-05-18

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

60 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT05816694 2023-04-18

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

50 enrolled

Thoracic

Thymoma

NCT00841828 2023-03-31

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

102 enrolled 10 charts

Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

47 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

62 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02067416 2023-02-02

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT05681728 2023-01-12

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

26 enrolled

Breast Neoplasms

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

150 enrolled

Breast Neoplasms

NCT01779050 2022-11-01

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Phase 2 Terminated

7 enrolled 8 charts

Breast Neoplasms

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05483439 2022-08-05

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

100 enrolled

Breast Neoplasms

NCT00496795 2022-06-29

DDP

100 enrolled

Breast Neoplasms

NCT05400993 2022-06-06

Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

59 enrolled

Breast Neoplasms

NCT02897050 2022-04-20

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Phase 2 Suspended

170 enrolled

Breast Neoplasms

NCT02050919 2022-03-21

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

20 enrolled 14 charts

Sarcoma

NCT02400567 2022-03-15

NeoPAL

125 enrolled

Neoadjuvant Operable Breast Cancer

NCT00193206 2021-11-23

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

123 enrolled 8 charts